Compare SFBC & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SFBC | ACOG |
|---|---|---|
| Founded | 1953 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.1M | 110.4M |
| IPO Year | 2012 | N/A |
| Metric | SFBC | ACOG |
|---|---|---|
| Price | $45.15 | $6.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 8.0K | ★ 59.4K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ 53.89 | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $146.05 |
| Revenue Next Year | N/A | $127.74 |
| P/E Ratio | $15.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.68 | $3.97 |
| 52 Week High | $51.69 | $10.88 |
| Indicator | SFBC | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 58.12 | 61.98 |
| Support Level | $43.74 | $6.46 |
| Resistance Level | $45.40 | $6.59 |
| Average True Range (ATR) | 1.10 | 0.58 |
| MACD | 0.07 | 0.13 |
| Stochastic Oscillator | 66.39 | 61.57 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.